SharesGrow.com Intrinsic Value of S&P & Nasdaq Contact Us

हिन्दी

← Back to all stocks

GSK plc GLAXF OTC

Other OTC • Healthcare • Drug Manufacturers - General • GB • USD

SharesGrow Score

SharesGrow Intrinsic Value

Negative cash flow

GSK plc (GLAXF) is a Drug Manufacturers - General company in the Healthcare sector, currently trading at $29.24. It has a SharesGrow Score of 70/100, indicating a above average investment profile with 4 out of 7 criteria passed.

Financials: revenue is $32.7B, +3.7%/yr average growth. Net income is $5.7B, growing at +2.4%/yr. Net profit margin is 17.5% (healthy). Gross margin is 72.5% (+5.1 pp trend).

Balance sheet: total debt is $17.7B against $16.4B equity (Debt-to-Equity (D/E) ratio 1.08, moderate). Current ratio is 0.82 (tight liquidity). Debt-to-assets is 29%. Total assets: $61.1B.

SharesGrow 7-Criteria breakdown: Value 75/100 (Pass), Growth 45/100 (Partial), Past 100/100 (Pass), Health 50/100 (Partial), Moat 90/100 (Pass), Future ?/100 (Fail), Income 70/100 (Pass).

GLAXF SharesGrow Score Overview

72/100

SharesGrow Score

Above average fundamentals

View full scorecard →

VALUE 75/100

Valuation — P/E, PEG, Forward PEG

GROWTH 45/100

Financials — average growth

PAST 100/100

strong — trend

HEALTH 50/100

Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is

MOAT 90/100

Gross margin is + market cap

FUTURE 0/100

Analyst outlook — as buy

INCOME 70/100

Net profit margin is

Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — GLAXF

GLAXF trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.

View details →

GLAXF: +3.7%/yr revenue is, +2.4%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

View details →

GLAXF: 4 / 4 years profitable. strong — 100%. Score = 4 / 4 × 100. ≥ 80 = Pass.

View details →

Balance sheet GLAXF: Debt-to-Equity (D/E) ratio 1.08 (moderate), Current ratio is 0.82 (tight liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

View details →

GLAXF: Gross margin is 72.5% (+5.1 pp trend), $117B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 90/100. ≥ 70 = Pass.

View details →

No analyst coverage available for this stock.

GLAXF: Net profit margin is 17.5%. healthy (≥15%). Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.

View details →

Stock Chart & Stats

Market Data

52-Week Range15.54-31.48

Volume200

Avg Volume (30D)2.41K

Market Cap$116.84B

Beta (1Y)0.35

Dividend Yield$0.8825

Share Statistics

EPS (TTM)1.41

Shares Outstanding$4.05B

IPO Date2010-01-05

Employees68,629

CEOLuke Victor Miels

Financial Highlights & Ratios

Revenue (TTM)$32.66B

Gross Profit$23.69B

EBITDA$11.88B

Net Income$5.72B

Operating Income$7.17B

Total Cash$3.41B

Total Debt$17.72B

Net Debt$14.32B

Total Assets$61.11B

Price / Earnings (P/E)20.7

Price / Sales (P/S)3.58

Analyst Forecast

Company Info

CountryGB

ExchangeOther OTC

CurrencyUSD

ISINGB00BN7SWP63

Price Chart

GLAXF

GSK plc ↗ · Other OTC

Healthcare • Drug Manufacturers - General

15.54 52WK RANGE 31.48

People Also View

Roche Holding AG

Roche Holding AG

Roche Holding AG

AstraZeneca PLC

AstraZeneca PLC

Contact Us

🎓

SharesGrow Academy

Learn how to calculate Intrinsic Value and find undervalued stocks.

Weekly live sessions

📧 [email protected]

📞 +65 8912 8000

Send us a message